SCHEMBL22319922

SCHEMBL22319922

CC(C)(C)[Si](C)(C)Oc1ccc(Nc2cc(C#N)cc(OCCCl)c2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.36
GAA P10253 7/20 0.36
KDM4E B2RXH2 6/20 0.36
EGFR P00533 1/20 0.33
ILK Q13418 1/20 0.33
MAPT P10636 7/20 0.33
ALDH1A1 P00352 5/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
TP53 P04637 2/20 0.33
HSD17B10 Q99714 2/20 0.33
LMNA P02545 2/20 0.33
MAPK1 P28482 2/20 0.33
KMT2A Q03164 5/20 0.32
MEN1 O00255 3/20 0.32
POLB P06746 1/20 0.32
ALOX15 P16050 1/20 0.32
HTT P42858 1/20 0.32
CDK1 P06493 1/20 0.32
KDR P35968 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22319881 0.96 HPGD (0.38) HPGDGAAKDM4EEGFRILK
SCHEMBL22319926 0.84 HPGD (0.33) HPGDGAAKDM4EMAPTALDH1A1
SCHEMBL22319969 0.81 MEN1 (0.40) EGFRMAPTMAPK1KMT2AMEN1
SCHEMBL22366388 0.79 ALDH1A1 (0.30) ALDH1A1L3MBTL1
SCHEMBL30093173 0.78 PREP (0.33) KDM4EMAPTKMT2AMEN1PREP
SCHEMBL16467813 0.78 GSK3B (0.46) HPGDGAAKDM4EMAPTSMN1; SMN2
SCHEMBL16411606 0.77 SLC2A1 (0.44) EGFRMAPTALDH1A1KMT2AMEN1
SCHEMBL22319995 0.76 MEN1 (0.40) EGFRMAPTKMT2AMEN1NPC1
SCHEMBL22320001 0.75 MEN1 (0.39) EGFRMAPTKMT2AMEN1NPC1
SCHEMBL16411365 0.73 TNIK (0.42) KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2023-12-05 US disclosed
EP-3700911-B1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2023-09-06 EP disclosed
EP-3700911-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier SAS (FR) 2020-09-02 EP disclosed
US-20200253993-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same C1R, F12, RDX HPGD 1169/4885GAA 820/4885KDM4E 2082/4885
US-20200253993-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME C1R, RDX, F12 HPGD 1447/4885GAA 862/4885KDM4E 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.